46
Participants
Start Date
August 6, 2015
Primary Completion Date
November 8, 2017
Study Completion Date
November 8, 2017
ISIS 443139 10 mg
ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
ISIS 443139 30 mg
ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
ISIS 443139 60 mg
ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
ISIS 443139 90 mg
ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
ISIS 443139 120 mg
ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Placebo
Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Charite University Berlin, Berlin
Ruhr-University of Bochum, Bochum
Ulm University Hospital, Ulm
University of British Columbia, Vancouver
University Hospitals Birmingham, Birmingham
Cambridge University Hospital, Cambridge
University Hospital of Wales, Cardiff
University College London, London
University of Manchester, St. Mary's Hospital, Manchester
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY